RxDoctor Payments DataLook up a doctor →

Esther Young, DO

Neurology · Rochester Hills, MINPI 1740230085

Payments from drug & device makers

$611,944in general payments, 2019–2025

Across 1,210 payments — averaging $505.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$355K
  • Sanofi$96K
  • Biohaven Pharmaceutical Holding Company Ltd.$53K
  • Pfizer$50K
  • Teva Pharmaceuticals USA, Inc.$19K
  • AbbVie$14K
  • plus $25K from 54 others
$6,349in research payments, 2019–2025

Across 1 payment — averaging $6349.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$6K

What the payments were for

  • Consulting fees$11,34015%
  • Speaking & faculty fees$45,78160%
  • Travel & lodging$2,1463%
  • Food & beverage$16,24021%
  • Education$2410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis269$354,888
Sanofi49$96,067
Biohaven Pharmaceutical Holding Company Ltd.49$52,898
Pfizer109$50,206
Teva Pharmaceuticals USA, Inc.54$18,850
AbbVie(2 entities)200$13,988
Eli Lilly5$10,002
Biohaven Pharmaceuticals, Inc.6$3,152
Bristol Myers Squibb86$2,718
Biogen29$2,570
EMD Serono, Inc.46$812
Amgen(2 entities)38$708
Johnson & Johnson33$388
UCB, Inc.27$371
Genentech USA, Inc.18$328
Supernus Pharmaceuticals, Inc.19$277
TG Therapeutics, Inc.6$245
Noctrix Health, Inc.2$242
GSK2$220
Lundbeck LLC11$211
Harmony Biosciences LLC7$209
Sumitomo Pharma America, Inc.12$195
Avanir Pharmaceuticals, Inc.11$178
Amneal Pharmaceuticals LLC9$147
Takeda Pharmaceuticals U.S.A., Inc.6$129
Bayer2$114
Adamas Pharmaceuticals, Inc.7$113
Bausch Health US, LLC9$111
Catalyst Pharmaceuticals, Inc.5$96
Eisai Inc.5$95
Acadia Pharmaceuticals Inc5$92
Neurelis, Inc.3$88
Jazz Pharmaceuticals Inc.5$84
Kyowa Kirin, Inc.4$80
MDD US Operations, LLC5$74
Banner Life Sciences, LLC3$74
Scilex Pharmaceuticals Inc.3$63
Otsuka America Pharmaceutical, Inc.4$62
Tanabe Pharma America, Inc.4$62
SK Life Science, Inc.2$48
Abbott2$46
Aprecia Pharmaceuticals, LLC2$46
Impel Pharmaceuticals Inc.2$45
E.r. Squibb & Sons, L.L.C.2$41
Medtronic(2 entities)2$41
Neurocrine Biosciences, Inc.2$39
Cala Health, Inc.2$39
AstraZeneca2$32
CSL Behring2$32
Zogenix Inc.2$32
Sunovion Pharmaceuticals Inc.3$30
Vanda Pharmaceuticals Inc.1$27
Lilly USA, LLC2$27
Argenx US, Inc.1$27
Axsome Therapeutics, Inc.1$23
Corium, LLC3$23
Cycle Pharmaceuticals Inc1$19
Acorda Therapeutics, Inc1$16
GE HealthCare1$15
Greenwich Biosciences, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$611,944 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$325,620
Medicare patients
1,177
Services billed
7,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MayzentSiponimod11$324,467
AubagioTeriflunomide15$174,706
VumerityDiroximel Fumarate18$151,629
Avonex Pen (4 Pack)Interferon Beta-1a19$147,659
CopaxoneGlatiramer Acetate17$116,174
AustedoDeutetrabenazine22$111,515
IngrezzaValbenazine Tosylate12$97,179
Kesimpta PenOfatumumab11$94,170
Teriflunomide58$80,897
Glatiramer Acetate34$75,609
Aimovig AutoinjectorErenumab-Aooe36$59,338
FingolimodFingolimod Hcl49$57,316
GlatopaGlatiramer Acetate22$56,879
Dimethyl Fumarate24$42,300
Emgality PenGalcanezumab-Gnlm31$40,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$354,888$324,46711 claims
Teva Pharmaceuticals USA, Inc.Copaxone, Austedo$18,850$227,68939 claims
SanofiAubagio$96,067$174,70615 claims
BiogenVumerity$2,570$151,62918 claims
Neurocrine Biosciences, Inc.Ingrezza$39$97,17912 claims
AbbVieUbrelvy$13,988$34,92726 claims
PfizerNurtec Odt$50,206$31,88121 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$147$26,45329 claims
UCB, Inc.Briviact$371$19,30014 claims
Neurelis, Inc.Valtoco$88$11,77513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.

Other neurology in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →